CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Net product sales	$ 737,562	$ 448,844	$ 1,939,954	$ 1,229,244
Sanofi collaboration revenue	224,735	132,925	593,201	406,028
Bayer HealthCare collaboration revenue	157,596	135,853	415,679	358,460
Technology licensing and other revenue	17,529	8,166	56,817	23,496
Total revenues	1,137,422	725,788	3,005,651	2,017,228
Expenses:
Research and development	425,924	337,728	1,159,367	919,608
Selling, general, and administrative	209,993	144,003	543,572	343,960
Cost of goods sold	67,199	33,655	170,624	91,073
Cost of collaboration and contract manufacturing	41,884	21,938	111,254	54,471
Total expenses	745,000	537,324	1,984,817	1,409,112
Income from operations	392,422	188,464	1,020,834	608,116
Other income (expense):
Investment and other income	2,603	2,591	4,533	5,205
Interest expense	(1,715)	(9,232)	(10,632)	(31,022)
Loss on extinguishment of debt	(21)	0	(16,927)	(10,787)
Total other income (expense)	867	(6,641)	(23,026)	(36,604)
Income before income taxes	393,289	181,823	997,808	571,512
Income tax expense	(182,891)	(98,448)	(516,746)	(323,481)
Net income	$ 210,398	$ 83,375	$ 481,062	$ 248,031
Net income per share - basic	$ 2.04	$ 0.83	$ 4.68	$ 2.47
Net income per share - diluted	$ 1.82	$ 0.73	$ 4.18	$ 2.19
Weighted average shares outstanding - basic	103,348	100,796	102,825	100,325
Weighted average shares outstanding - diluted	115,944	117,423	115,144	113,203
Statements of Comprehensive Income
Net income	$ 210,398	$ 83,375	$ 481,062	$ 248,031
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities, net of tax	(11,432)	22,632	(44,530)	28,083
Comprehensive income	$ 198,966	$ 106,007	$ 436,532	$ 276,114